Deutsche Bank’s exchange-traded fund platform, db X-trackers, has launched an ETF to help finance the fight against Aids, tuberculosis and malaria.
The db x-trackers Global Fund Supporters ETF, which tracks the Dow Jones Global Fund 50 Index to Fight Aids, Tuberculosis and Malaria, has launched on the Frankfurt Stock Exchange.
The index tracks the performance of the largest public companies that support the mission of the Global Fund.
db X-trackers’ management revenues in respect of the Global Fund Supporters ETF, after costs for running the fund, will go towards the Global Fund, a public/private partnership dedicated to attracting and distributing resources to prevent and treat HIV/Aids, tuberculosis and malaria.
To date, the Global Fund has committed USD19.8bn in 149 countries to support large-scale prevention, treatment and care programmes.
“By making the Dow Jones Global Fund 50 Index available in ETF format we have made it truly investable. We fully support the Global Fund and its efforts to combat these terrible diseases, and are happy to direct profits from this new product to their cause,” says Thorsten Michalik, global head of db X-trackers. “We’ve seen a massive uptake in our ETFs since we launched in 2007. With ever increasing numbers of investors embracing the products, and with more of those investors wishing to invest along socially-conscious lines, we are confident that the db x-trackers Global Fund Supporters ETF will be a success.”
The Global Fund Supporters ETF uses physical replication to track its index. This is a first for db X-trackers, which traditionally replicates indices using a swap-based – also commonly referred to as synthetic – replication method.
